| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/25/2001 | WO2001005968A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 01/25/2001 | WO2001005965A1 Non-human mammal with tissue specific modified glucocorticoid receptor |
| 01/25/2001 | WO2001005947A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | WO2001005937A2 Conversion of a watson-crick dna to a hoogsteen-paired duplex |
| 01/25/2001 | WO2001005834A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | WO2001005826A2 Chimeric polypeptides of serum albumin and uses related thereto |
| 01/25/2001 | WO2001005823A2 Tryptase inhibitor |
| 01/25/2001 | WO2001005810A2 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN αVβ¿6? |
| 01/25/2001 | WO2001005805A2 Novel c-19-halogen-substituted, 5-substituted, 5-substituted or 6,10 carbocyclically condensed steroids of the androst-9(11)-ene-series, methods for the production and use thereof |
| 01/25/2001 | WO2001005802A1 Antisense modulation of fadd expression |
| 01/25/2001 | WO2001005790A1 New compounds |
| 01/25/2001 | WO2001005780A1 Coumarone analogues |
| 01/25/2001 | WO2001005776A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 01/25/2001 | WO2001005771A1 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists |
| 01/25/2001 | WO2001005756A1 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors |
| 01/25/2001 | WO2001005753A1 Diacylhydrazine derivatives |
| 01/25/2001 | WO2001005436A1 Method for producing antibodies in egg yolk and use of resulting antibodies |
| 01/25/2001 | WO2001005435A2 Antisense therapy for hormone-regulated tumors |
| 01/25/2001 | WO2001005430A1 Sustained release drug dispersion delivery device |
| 01/25/2001 | WO2001005427A1 Psca: prostate stem cell antigen and uses thereof |
| 01/25/2001 | WO2001005425A2 Combined preparations comprising daunorubicin derivatives and her2 antibodies |
| 01/25/2001 | WO2001005423A1 Use of vasoactive intestinal peptide (vip) for modulating the development of a specific immune response |
| 01/25/2001 | WO2001005421A1 Methods employing bacterial toxin-antitoxin systems for killing eukaryotic cells |
| 01/25/2001 | WO2001005414A1 Algae protein polysaccharide extraction and use thereof |
| 01/25/2001 | WO2001005411A1 Compositions addressing inflammation and/or degenerative disorders |
| 01/25/2001 | WO2001005402A1 Preventive and therapeutic agents for cancer |
| 01/25/2001 | WO2001005397A1 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same |
| 01/25/2001 | WO2001005382A1 Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds |
| 01/25/2001 | WO2001005380A1 Sustained release compositions, process for producing the same and use thereof |
| 01/25/2001 | WO2001005372A2 A liposome composition having resistance to freeze/thaw damage |
| 01/25/2001 | WO2001005353A2 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |
| 01/25/2001 | WO2001005316A1 Real-time monitoring of photodynamic therapy over an extended time |
| 01/25/2001 | WO2000066587A3 Polyamines and their use in therapy |
| 01/25/2001 | WO2000066111B1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions |
| 01/25/2001 | WO2000066093A3 Combined preparations comprising morpholine anthracyclines and anticancer agent |
| 01/25/2001 | WO2000061174A3 Use of pegylated interferon alpha for renal cell carcinoma treatment |
| 01/25/2001 | WO2000061173A3 Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy |
| 01/25/2001 | WO2000060080A3 Molecules of the immune system |
| 01/25/2001 | WO2000059946A8 Hydroxymatairesinol in cancer prevention |
| 01/25/2001 | WO2000058473A3 Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| 01/25/2001 | WO2000054815A3 Expression of dna or proteins in c. elegans |
| 01/25/2001 | WO2000044740A3 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 01/25/2001 | DE19933164A1 Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten New carboxylic acid derivatives with 5,6-substituted pyrimidine ring, their preparation and use as endothelin receptor antagonists |
| 01/25/2001 | CA2381327A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | CA2379983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | CA2379662A1 Preventive and therapeutic agents for cancer |
| 01/25/2001 | CA2379627A1 Inhibitor proteins |
| 01/25/2001 | CA2379545A1 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists |
| 01/25/2001 | CA2379489A1 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same |
| 01/25/2001 | CA2379366A1 A liposome composition having resistance to freeze/thaw damage |
| 01/25/2001 | CA2379325A1 Methods employing bacterial toxin-antitoxin systems for killing eukaryotic cells |
| 01/25/2001 | CA2379041A1 Diacylhydrazine derivatives |
| 01/25/2001 | CA2379022A1 Cyclic peptide derivatives as inhibitors of integrin .alpha.v.beta.6 |
| 01/25/2001 | CA2378946A1 Psca: prostate stem cell antigen and uses thereof |
| 01/25/2001 | CA2378930A1 Electron transfer proteins |
| 01/25/2001 | CA2378917A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | CA2378829A1 Sustained release drug dispersion delivery device |
| 01/25/2001 | CA2378714A1 Sustained release compositions, methods for producing the same and uses thereof |
| 01/25/2001 | CA2378249A1 Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis |
| 01/25/2001 | CA2378202A1 New compounds |
| 01/25/2001 | CA2377247A1 Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor |
| 01/25/2001 | CA2376641A1 Chimeric polypeptides of serum albumin and uses related thereto |
| 01/25/2001 | CA2376518A1 Conversion of a watson-crick dna to a hoogsteen-paired duplex |
| 01/25/2001 | CA2375467A1 Antisense therapy for hormone-regulated tumors |
| 01/25/2001 | CA2340721A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 01/24/2001 | EP1070727A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction |
| 01/24/2001 | EP1070707A1 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 01/24/2001 | EP1070703A1 Cyclobutene derivatives |
| 01/24/2001 | EP1070502A2 Compositions and methods for treating or preventing inflammatory diseases |
| 01/24/2001 | EP1070140A1 Compositions and methods for treating cells having double minute dna |
| 01/24/2001 | EP1070129A2 Dadd, death activator death domain protein |
| 01/24/2001 | EP1070125A2 Human nucleic acid sequences from normal breast tissue |
| 01/24/2001 | EP1070122A2 Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| 01/24/2001 | EP1070118A1 Modified adenovirus containing a fiber replacement protein |
| 01/24/2001 | EP1070085A1 DUAL A v?b 3? AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS |
| 01/24/2001 | EP1070069A1 Bicyclic hydroxamic acid derivatives |
| 01/24/2001 | EP1070068A1 Granulatimide derivatives for use in cancer treatment |
| 01/24/2001 | EP1070067A1 Cytotoxic alkaloid derivatives including asmarine a and b isolated from a sponge |
| 01/24/2001 | EP1070065A1 Azabicyclic 5ht1 receptor ligands |
| 01/24/2001 | EP1070064A1 Antagonists of gonadotropin releasing hormone |
| 01/24/2001 | EP1070060A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists |
| 01/24/2001 | EP1070059A1 Chromanone and thiochromanone derivatives |
| 01/24/2001 | EP1070058A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| 01/24/2001 | EP1070057A1 7-hexanoyltaxol and methods for preparing the same |
| 01/24/2001 | EP1069919A2 Stimulus sensitive gel with radioisotope and methods of making |
| 01/24/2001 | EP1069917A1 Novel complementing receptor-ligand pairs and adoptive immunotherapy using same |
| 01/24/2001 | EP1069915A2 Hydroxylation activated drug release |
| 01/24/2001 | EP1069911A1 A novel nitroreductase and therapeutic uses therefor |
| 01/24/2001 | EP1069910A1 Adjuvant compositions |
| 01/24/2001 | EP1069908A2 Methods and modified cells for the treatment of cancer |
| 01/24/2001 | EP1069906A1 Conjugates useful in the treatment of prostrate cancer |
| 01/24/2001 | EP1069903A1 Novel nucleoside analogs and uses in treating disease |
| 01/24/2001 | EP1069901A1 Calcilytic compounds and method of use |
| 01/24/2001 | EP1069897A1 Methods for inhibiting mrp1 |
| 01/24/2001 | EP1069894A1 Spisulosine compounds having antitumour activity |
| 01/24/2001 | EP0971585A4 Method of inhibiting cancer growth |
| 01/24/2001 | CN1281512A Selective killing and diagnosis of P53+ neoplastic cells |
| 01/24/2001 | CN1281468A Treatment with anti-ErbB2 antibodies |
| 01/24/2001 | CN1281441A Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors |
| 01/24/2001 | CN1281436A N-Benzyl-3-indenylacetamides derivatives for treating neoplasia |